Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer. Strong support from leading investors and global pharma partners continues to ...
The MarketWatch News Department was not involved in the creation of this content. -- Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する
フィードバック